Login to Your Account

Rights to Schizophrenia Drug Worth up to $702M for Addex

By Donna Young

Friday, January 4, 2008
Swiss biotech Addex Pharmaceuticals has granted rights to Merck & Co. Inc. to develop ADX63365, an investigational treatment for schizophrenia, in a deal potentially worth $702 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription